Forte Biosciences (FBRX) Total Liabilities (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Total Liabilities data on file, last reported at $25.1 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 47.06% year-over-year to $25.1 million in Q1 2026; TTM through Mar 2026 was $25.1 million, a 47.06% decrease from a year earlier, with the FY2025 full-year figure at $21.8 million, up 139.93% from the prior year.
• Total Liabilities for Q1 2026 stood at $25.1 million, up from $21.8 million in the prior quarter.
• Over the last five years, Total Liabilities for FBRX reached as high as $107.8 million in Q2 2025 and fell as low as $9.1 million in Q4 2024.
• Historically, Total Liabilities has averaged $41.6 million across 5 years, with a median of $39.0 million in 2023.
• Across the five-year window, Total Liabilities plunged 76.7% in 2024 and soared 441.01% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $42.0 million in 2022, then decreased by 7.18% to $39.0 million in 2023, then plunged by 76.7% to $9.1 million in 2024, then soared by 139.93% to $21.8 million in 2025, then increased by 15.31% to $25.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $25.1 million in Q1 2026, $21.8 million in Q4 2025, and $97.1 million in Q3 2025.